Literature DB >> 28509295

Antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis with membranous nephropathy treated using thiamazole.

Tomoko Kakita1, Katsuyuki Nagatoya2, Hiroki Takimoto1, Hirohisa Matsuda1, Tatsuhiko Mori1, Ayako Kawaguchi1,3, Toru Inoue1,4.   

Abstract

A 21-year-old woman with nephrotic syndrome was referred to our hospital. She had congenital diaphragmatic hernia, hypoxic ischemic encephalopathy, and mental retardation, and had been treated for hyperthyroidism with thiamazole in another hospital. Serum creatinine was 37.8 μmol/L and antineutrophil cytoplasmic antibody against myeloperoxidase (MPO-ANCA) was 39 EU. Urinalyses were 3+ for proteins and 3+ for occult blood. A renal biopsy was performed. An examination using light microscopy (LM) revealed necrotizing glomerulonephritis with crescent formation. Immunofluorescence microscopy showed granular staining with immunoglobulin G and complement component 3 along the capillary walls. Electron microscopy (EM) disclosed subepithelial dense deposits. A renal biopsy suggested necrotizing glomerulonephritis with membranous nephropathy (MN) in stages I or II. Since many cases of drug-induced ANCA-associated glomerulonephritis (AAG) have been reported, we stopped thiamazole and treated with corticosteroid. The MPO-ANCA titer became negative 49 days after the initiation of treatment. Two years after the first treatment, the MPO-ANCA titer became elevated again and was 82 EU. The patient was administered cyclophosphamide and prednisone. However, the MPO-ANCA titer did not decrease. A renal biopsy was performed again 3 years after the first renal biopsy. LM revealed no crescentic formation but demonstrated spike formations along the glomerular basement membrane. EM also disclosed subepithelial dense deposits, but less than the first biopsy. The renal biopsy suggested MN in stages II or III. AAG was regarded as inactive after corticosteroid treatment. Therefore, ciclosporin administration was started. In conclusion, we experienced a rare case of AAG complicated with MN. The histopathologic results showed that immunosuppressive therapy seemed to be effective in treating crescentic glomerulonephritis; furthermore, it reduced proteinuria but could not reduce the MPO-ANCA titer.

Entities:  

Keywords:  ANCA-associated crescentic glomerulonephritis; Antithyroid drug; Membranous nephropathy

Year:  2013        PMID: 28509295      PMCID: PMC5411549          DOI: 10.1007/s13730-013-0060-7

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  9 in total

Review 1.  Drug-induced vasculitis: a clinical and pathological review.

Authors:  M Radić; D Martinović Kaliterna; J Radić
Journal:  Neth J Med       Date:  2012-01       Impact factor: 1.422

Review 2.  Approach to the pediatric patient with Graves' disease: when is definitive therapy warranted?

Authors:  Andrew J Bauer
Journal:  J Clin Endocrinol Metab       Date:  2011-03       Impact factor: 5.958

3.  [An elderly case of ANCA-positive membranous nephropathy].

Authors:  Shizue Sekine; Wako Yumura; Yuko Tanaka; Shinya Suganuma; Takako Onuki; Keiko Uchida; Akira Kawashima; Kazuho Honda; Kosaku Nitta; Hiroshi Nihei
Journal:  Nihon Jinzo Gakkai Shi       Date:  2002-01

4.  Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole.

Authors:  Norio Wada; Masaya Mukai; Michifumi Kohno; Atsushi Notoya; Tomohiro Ito; Narihito Yoshioka
Journal:  Endocr J       Date:  2002-06       Impact factor: 2.349

5.  Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis.

Authors:  Won K Han; Hyon K Choi; Rachel M Roth; Robert T McCluskey; John L Niles
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

6.  Pathologic differentiation between lupus and nonlupus membranous glomerulopathy.

Authors:  J C Jennette; S S Iskandar; F G Dalldorf
Journal:  Kidney Int       Date:  1983-09       Impact factor: 10.612

7.  Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis.

Authors:  Samih H Nasr; Samar M Said; Anthony M Valeri; Michael B Stokes; Naveed N Masani; Vivette D D'Agati; Glen S Markowitz
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 8.237

8.  Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides.

Authors:  Branka Bonaci-Nikolic; Milos M Nikolic; Sladjana Andrejevic; Svetlana Zoric; Mirjana Bukilica
Journal:  Arthritis Res Ther       Date:  2005-07-13       Impact factor: 5.156

9.  MPO-ANCA crescentic glomerulonephritis complicated by membranous nephropathy: MPO demonstrated in epimembranous deposits.

Authors:  Kei Matsumoto; Hirokazu Honda; Takanori Shibata; Daisuke Sanada; Yukihiro Wada; Eijin Ashikaga; Aki Kuroki; Kozo Kitazawa; Tadao Akizawa
Journal:  NDT Plus       Date:  2009-08-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.